Evaluation of Serum Proinflammatory Cytokine IL‐17A and Tight Junction Protein Claudin‐1 in Psoriasis
Contrast Media & Molecular Imaging · 2022-01 · 2022 (1)
DOI: 10.1155/2022/6092808 ↗Kurz gefasst
Fachartikel in der Zeitschrift Contrast Media & Molecular Imaging, online erschienen am 07.03.2022. Verfasst von Lina Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China. Hauptthemen laut MEDLINE: Psoriasis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
This study aimed to estimate serum IL‐17A and Claudin‐1 levels, investigate their correlation, and evaluate their diagnostic significance as potential blood‐based biomarkers in psoriasis.
Methods
Serum IL‐17A and Claudin‐1 concentrations were determined using enzyme‐linked immunosorbent assay (ELISA). Statistical analyses were performed to determine differences in serum levels of IL‐17A and Claudin‐1, their bivariable correlation with psoriasis severity, as Psoriasis Area Severity Index (PASI), and their predictive abilities using receiver operating characteristic (ROC) curves.
Results
Significantly higher IL‐17A and lower Claudin‐1 levels were found in psoriasis ( p < 0.05). PASI did not correlate significantly with either IL‐17A or Claudin‐1 in psoriasis and their subtypes. The only significant correlation between serum IL‐17A and Claudin‐1 was shown in late‐onset psoriasis ( r = 0 . 630 , p = 0 . 028 ). ROC curve analysis indicated the serum IL‐17A, serum Claudin‐1, and combination of IL‐17A and serum Claudin‐1 for predicting psoriasis with the areas under the curve (AUC) of 0.951 ( p < 0.0001), 0.709 ( p = 0.0119), and 0.949 ( p < 0.0001), respectively. Moreover, the potential role in distinguishing between early‐onset and late‐onset psoriasis: we obtained serum IL‐17A, serum Claudin‐1, and their combination AUC of 0.590 ( p = 0.3126), 0.741 ( p = 0.0045), and 0.741 ( p = 0.0067), respectively. However, none of the serum IL‐17A, serum Claudin‐1, and their combination was well‐performed discriminating mild psoriasis from moderate‐to‐severe psoriasis with AUC of 0.553 ( p = 0.5596), 0.518 ( p = 0.8539), and 0.559 ( p = 0.5225), respectively.
Conclusion
These preliminary results suggest that the serum Claudin‐1 as a potential biomarker and the relationship and possible regulatory interactions between IL‐17A and Claudin‐1 in psoriasis are distinguishable by age of onset.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
ORCID-Profile: Lina Xu, Jianjun Qiao, Hong Fang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Xu, L., Pan, Y., Tang, S., Bai, J., Wu, Y., Qiao, J., & Fang, H. (2022). Evaluation of Serum Proinflammatory Cytokine IL‐17A and Tight Junction Protein Claudin‐1 in Psoriasis. Contrast Media & Molecular Imaging, 2022(1). https://doi.org/10.1155/2022/6092808
Vancouver
Xu L, Pan Y, Tang S, Bai J, Wu Y, Qiao J, et al. Evaluation of Serum Proinflammatory Cytokine IL‐17A and Tight Junction Protein Claudin‐1 in Psoriasis. Contrast Media & Molecular Imaging. 2022;2022(1). doi:10.1155/2022/6092808
BibTeX
@article{Xu2022,
author = {Xu, Lina and Pan, Yunlei and Tang, Shunli and Bai, Juan and Wu, Yinhua and Qiao, Jianjun and Fang, Hong},
title = {Evaluation of Serum Proinflammatory Cytokine IL‐17A and Tight Junction Protein Claudin‐1 in Psoriasis},
journal = {Contrast Media & Molecular Imaging},
year = {2022},
volume = {2022},
number = {1},
doi = {10.1155/2022/6092808}
}
EUVIMED